Accretion Dilution Analysis: How to Model EPS Impact of an Acquisition
Accretion dilution analysis is the M&A model that answers the only question a public-company acquirer’s board really cares about on announcement day: will this deal raise or lower our pro forma earnings per share in year one, and by how much. The math is straightforward arithmetic at the headline level, but the inputs (synergy phasing, transaction expenses, financing mix, purchase accounting amortization, foregone interest income, share count walk) are where bankers at Goldman Sachs, Morgan Stanley, Centerview, Evercore, Lazard, and PJT Partners earn their fees. This guide walks the complete 2026 build of an accretion dilution model, including the EPS bridge, the breakeven synergy table, the cost of debt versus cost of equity decision, and the regulatory disclosure footprint under SEC Article 11 pro forma rules.
The model matters because Wall Street has a long memory for deals that promised accretion and delivered dilution. AOL-Time Warner (2000), Sprint-Nextel (2005), HP-Autonomy (2011), and Bayer-Monsanto (2018) all carried investment banker decks that showed first-year accretion that never materialized once integration costs, intangible amortization, and revenue dis-synergies hit the income statement. The Delaware Court of Chancery has cited misleading accretion projections in fiduciary duty cases including In re Pure Resources Shareholders Litigation (2002) and several post-Corwin proxy disclosure suits (see Delaware Court of Chancery opinions database), and the SEC Division of Corporation Finance regularly comments on Item 11 and Item 14 pro forma EPS presentations in merger proxies (SEC Corp Fin staff guidance).
Quick-Reference: Accretion Dilution Analysis in 90 Seconds
| Item | Detail |
|---|---|
| Also known as | Accretion dilution model, accretion dilution, accretion and dilution, A/D analysis, EPS bridge, pro forma EPS model |
| What it measures | Change in pro forma diluted EPS in year 1, year 2, year 3 versus standalone acquirer EPS |
| Headline output | Accretion percent (positive) or dilution percent (negative) versus standalone EPS |
| Inputs needed | Acquirer standalone net income and share count, target net income, deal price, financing mix, synergy schedule, transaction expenses, amortization of identifiable intangibles, foregone interest |
| Output benchmark | Accretion of 1 to 7 percent year 1 is typical for strategic bolt-ons. Dilution greater than 5 percent triggers proxy advisory pushback from ISS and Glass Lewis |
| Typical use cases | Public-company board approval, fairness opinion exhibit, sell-side pitch, investor day, SEC proxy filing, ratings agency presentation |
| Time to build (first pass) | 3 to 6 hours for a clean single-jurisdiction deal, 20 to 40 hours for cross-border with multiple currencies, step-ups, and earn-outs |
| Refresh cadence on live deal | Daily during negotiation, hourly during signing day price moves |
| Where it sits in the football field | Not a valuation method itself. It is the affordability test that confirms the bid does not destroy near-term shareholder value |
| Breakeven synergy concept | The minimum recurring run-rate synergy that makes the deal EPS-neutral in year 1 |
What Accretion Dilution Analysis Actually Measures
An accretion dilution model takes the acquirer’s standalone projected net income, adds the target’s standalone projected net income, layers in deal-specific adjustments, divides by the new pro forma share count, and compares the result to the standalone acquirer EPS. If pro forma EPS is higher, the deal is accretive. If lower, it is dilutive.
The formula at the top of every accretion dilution analysis is:
Pro Forma EPS = (Acquirer Net Income + Target Net Income + Pre-Tax Synergies x (1 – Tax Rate) – After-Tax Incremental Interest Expense – After-Tax Foregone Interest Income – After-Tax New Intangible Amortization – After-Tax One-Time Integration Costs) / (Acquirer Diluted Shares + New Shares Issued)
Accretion or dilution percent then equals (Pro Forma EPS / Standalone Acquirer EPS) – 1. The arithmetic looks tidy but every line item carries judgment. Synergies are timed and phased. Interest expense depends on financing mix and rate environment. Intangible amortization depends on purchase price allocation under ASC 805 Business Combinations. Three banks running the same deal on the same day will produce three different EPS bridges, and any of them can be defended.
The Four Drivers That Decide Accretion or Dilution
Strip out the noise and only four variables move the answer. Every senior banker memorizes this hierarchy:
| Driver | How it moves accretion | Typical sensitivity |
|---|---|---|
| 1. Financing mix (cash vs. stock vs. debt) | Cheaper financing (low after-tax cost of debt) increases accretion. Stock issued at a low acquirer P/E destroys accretion | Each 10 point shift in stock-to-cash mix can move year 1 EPS by 2 to 5 percent |
| 2. Deal premium paid | Higher premium means more shares issued or more debt taken, both dilute | Each 5 point premium change moves year 1 EPS by 1 to 3 percent |
| 3. Synergies (run-rate and phasing) | Cost synergies recognized faster, revenue synergies recognized later (or never) | Every $100M of pre-tax run-rate synergy on a $5B deal can add 4 to 8 percent accretion at full phase-in |
| 4. Target P/E relative to acquirer P/E | If acquirer trades at higher P/E than the implied P/E paid for target, the deal is mechanically accretive before any synergies (Rule of P/E) | The single largest driver in all-stock deals |
The Rule of P/E (sometimes called the Bootstrap rule) is the shortcut every M&A analyst at Houlihan Lokey, Lincoln International, Raymond James, William Blair, or Harris Williams learns in week one: in an all-stock deal with no synergies and no transaction costs, the deal is accretive if and only if the acquirer’s P/E is higher than the implied P/E paid for the target. The mechanism is simple. If you trade at 25x earnings and you buy a company at 15x earnings using your own stock as currency, you give up 60 cents of earnings via dilution to gain 100 cents of earnings via consolidation. Net accretion: 40 cents per dollar.
For the strategic-buyer thinking that underpins these deals, see our breakdown at M&A advisor and the analyst-track context at sell-side analyst.
Step-by-Step Build: A Worked 2026 Example with Sources and Uses
The cleanest way to learn accretion dilution analysis is to build one. Below is a complete worked example using fictional Acquirer Co. buying fictional Target Co. for a fixed enterprise value with a mix of cash, new debt, and stock issued at the acquirer’s current trading price.
| Input | Acquirer Co. | Target Co. |
|---|---|---|
| Share price (deal date) | $80.00 | $40.00 |
| Diluted shares outstanding (millions) | 200.0 | 50.0 |
| Equity value (millions) | $16,000 | $2,000 |
| Net debt (millions) | $2,000 | $500 |
| Forward-year net income (millions) | $1,200 | $120 |
| Standalone EPS (forward year) | $6.00 | $2.40 |
| P/E multiple (forward) | 13.3x | 16.7x (at $40 standalone) |
| Excess cash for funding | $800 | n/a |
| Effective tax rate | 23.0% | 23.0% |
Acquirer offers $50.00 per Target share, a 25 percent premium to the $40.00 unaffected price. Total equity consideration: $2,500M. Acquirer assumes Target’s $500M of net debt. Total enterprise consideration: $3,000M. Funded with $800M existing cash, $1,500M new five-year senior unsecured notes at 5.75 percent (priced to current investment-grade BBB credit per Federal Reserve H.15 selected interest rates), and $700M of newly issued Acquirer stock at $80.00 (8.75M new shares).
Step 1: Sources and uses. Every accretion dilution deck opens with this page.
| Uses of funds ($M) | Amount | Sources of funds ($M) | Amount |
|---|---|---|---|
| Purchase of Target equity | 2,500.0 | Existing Acquirer cash | 800.0 |
| Refinance Target debt | 500.0 | New senior notes (5.75%, 5-yr) | 1,500.0 |
| M&A advisory + legal + financing fees | 45.0 | New Acquirer stock issued | 700.0 |
| Capitalized financing costs | 15.0 | New revolver draw | 60.0 |
| Total uses | 3,060.0 | Total sources | 3,060.0 |
The $45M fee block is consistent with the 1.5 percent total transaction cost benchmark for U.S. middle-market and lower-large-cap deals reported by PitchBook 2025 advisory fee data. Mega-deal fees scale lower (0.4 to 0.7 percent on $20B-plus transactions, per Refinitiv Deal Insights).
Step 2: Calculate the new pro forma share count. 200.0M acquirer diluted shares plus 8.75M new shares issued ($700M / $80.00) equals 208.75M pro forma diluted shares.
Step 3: Build the income statement walk.
| Income statement line ($M) | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Acquirer standalone net income | 1,200.0 | 1,260.0 | 1,323.0 |
| Target standalone net income | 120.0 | 129.6 | 140.0 |
| Pre-tax cost synergies (phased 25/75/100) | 25.0 | 75.0 | 100.0 |
| Pre-tax revenue synergies (phased 0/20/50) | 0.0 | 10.0 | 25.0 |
| Pre-tax integration costs (front-loaded) | (40.0) | (20.0) | (5.0) |
| New intangible amortization (10-yr SL on $400M PPA step-up) | (40.0) | (40.0) | (40.0) |
| Foregone interest income on $800M cash at 4.5% | (36.0) | (36.0) | (36.0) |
| Incremental interest expense on $1,500M at 5.75% | (86.3) | (86.3) | (86.3) |
| After-tax adjustments at 23% | (136.5) | (74.9) | (32.6) |
| Pro forma net income | 1,183.5 | 1,314.7 | 1,430.4 |
| Pro forma EPS (208.75M shares) | $5.67 | $6.30 | $6.85 |
| Standalone acquirer EPS | $6.00 | $6.30 | $6.62 |
| Accretion (Dilution) percent | (5.5%) | 0.0% | 3.6% |
The headline output: 5.5 percent dilution in year 1, breakeven in year 2, 3.6 percent accretion in year 3. That is a textbook “J-curve” deal, dilutive on impact, accretive over the cycle. The board will press on three questions: how confident are we in the year 3 synergy number, what happens if integration costs run over, and is there a financing structure that converts year 1 dilution to year 1 accretion.
Financing Mix and Exchange Ratio Mechanics
Financing choice is where the accretion dilution model gets weaponized in negotiation. The three pure forms:
- All cash (balance sheet): Most accretive on day one if the acquirer is sitting on excess cash earning Treasury rates (4 to 5 percent in 2026 per the U.S. Treasury daily yield curve). Foregone interest income at after-tax 3.0 to 4.0 percent is almost always cheaper than the target’s earnings yield.
- All new debt: Accretive if after-tax cost of debt is lower than the target’s earnings yield. At a 5.75 percent pre-tax coupon and 23 percent tax rate, after-tax cost is 4.43 percent. Target trading at 15x earnings has an earnings yield of 6.67 percent. Net positive: 2.24 percent on every dollar of debt funded.
- All stock: Accretive only if Acquirer P/E exceeds implied target P/E (the Rule of P/E above). Adds zero balance sheet debt, which preserves credit rating and dry powder for the next deal.
The 2026 cost-of-capital framework every associate keeps on the desk:
| Financing source | 2026 pre-tax cost | After-tax cost at 23% |
|---|---|---|
| Excess cash (foregone interest) | 4.5% | 3.47% |
| Revolver draw (SOFR + 125 bps) | 6.20% | 4.77% |
| 5-year senior unsecured (BBB) | 5.75% | 4.43% |
| 10-year senior unsecured (BBB) | 6.10% | 4.70% |
| 10-year senior unsecured (BB) | 7.85% | 6.04% |
| New common stock (cost = 1 / Acquirer P/E) | varies | no tax shield |
| Convertible notes (5-yr investment grade) | 3.50% coupon | ~5.5% all-in |
For investment-grade benchmarks see the ICE BofA BBB US Corporate Index Effective Yield (FRED). For high yield, the ICE BofA US High Yield Index Effective Yield tracks the BB and B band that funds aggressive bolt-ons.
In stock-for-stock deals the headline price is set by an exchange ratio. Two structures dominate: a fixed exchange ratio (acquirer takes price risk between signing and closing, used in Disney/Fox 2019 and Microsoft/Activision early drafts) or a fixed-value exchange ratio where the ratio floats based on acquirer VWAP over a measurement period. Collared structures hybridize the two within a price band. The accretion dilution model must be run on at least two scenarios (low and high acquirer price) when the structure is anything other than fixed-ratio. Cross-border deals add an FX layer: the target’s earnings translate at the period-average rate under FASB ASC 830, and a 10 percent move in EUR/USD can swing pro forma EPS by 1 to 4 percent. Deal-contingent forwards quoted by J.P. Morgan, Citi, Barclays, and HSBC at 25 to 75 basis points above spot forward are the standard hedge. Microsoft’s 2014 acquisition of Nokia’s mobile business gave back roughly $250M of expected first-year EPS contribution to adverse EUR/USD between announcement and close (see Microsoft 10-K filings, FY2015).
Synergies: Cost, Revenue, and the Phasing Curve
Synergy is the most contested line in the accretion dilution model. Cost synergies (procurement, headcount, real estate, IT consolidation) are estimated at 5 to 12 percent of the target’s operating expense base for in-market consolidation deals, per repeated empirical work by Bain & Company M&A practice publications and BCG’s M&A studies. Revenue synergies (cross-sell, pricing power, distribution expansion) are notoriously over-estimated. McKinsey M&A research consistently reports that only about 50 percent of revenue synergies projected at announcement materialize, versus roughly 80 percent for cost synergies.
Standard phasing assumptions defensible in a board meeting:
| Synergy category | Year 1 | Year 2 | Year 3 | Run-rate by |
|---|---|---|---|---|
| Cost synergies (procurement, IT, real estate) | 25% | 75% | 100% | Month 24-30 |
| Cost synergies (headcount, severance-driven) | 15% | 60% | 95% | Month 30-36 |
| Revenue synergies (cross-sell) | 0% | 20% | 50% | Year 4-5 |
| Revenue synergies (pricing harmonization) | 10% | 40% | 70% | Year 3 |
| Tax synergies (NOL utilization) | 50% | 90% | 100% | Subject to 382 limits |
The IRC Section 382 limitation caps annual NOL usage by an acquired loss corporation at the long-term tax-exempt rate multiplied by the acquirer’s purchase price equity value. For 2026 the long-term tax-exempt rate published monthly by the IRS sits in the 4.0 to 4.5 percent range (see IRS Applicable Federal Rates). One-time integration costs typically run 1 to 2 times the year 1 cost synergy estimate, per the Deloitte M&A integration benchmarks.
Purchase Price Allocation and Intangible Amortization
The acquisition method under ASC 805 requires the buyer to allocate the purchase price across the target’s tangible and intangible assets at fair value. Identifiable intangibles (customer relationships, developed technology, trade names, non-compete agreements, in-process R&D) are amortized over estimated useful lives. Goodwill is not amortized but tested annually for impairment under ASC 350. The amortization line drops directly into the EPS bridge as a non-cash but P&L-real expense.
| Intangible category | Typical useful life | Method |
|---|---|---|
| Customer relationships | 8 to 15 years | Accelerated or straight-line |
| Developed technology | 5 to 8 years | Straight-line |
| Trade names (definite life) | 10 to 20 years | Straight-line |
| Trade names (indefinite life) | Not amortized | Impairment test only |
| Non-compete agreements | Term of contract (3 to 5 years) | Straight-line |
| In-process R&D | Indefinite until project completes | Straight-line post-completion |
| Backlog and order book | 1 to 3 years | Pattern of revenue |
The AICPA Accounting and Valuation Guide on Business Combinations sets the technical methodology that valuation firms (Kroll, Houlihan Lokey FAS, BDO, Stout, Marshall & Stevens) apply when delivering a 805 valuation report. Fees for a complete PPA on a mid-size deal run $75,000 to $300,000. For deals where intangibles are a small share of consideration (industrial roll-ups), the amortization line is often immaterial. For tech and SaaS deals where developed technology and customer relationships together represent 50 to 80 percent of consideration, amortization can wipe out 20 to 40 percent of the deal’s EPS contribution in year 1.
Adjusted EPS, Earnouts, and Contingent Consideration
Because intangible amortization is non-cash, most acquirers present accretion dilution analysis on both a GAAP basis and an adjusted or “cash EPS” basis that adds back deal-related intangible amortization. The SEC has tightened its rules on non-GAAP presentation under Regulation G and the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures, and the staff regularly challenges “cash EPS” presentations that exclude items industry peers would not exclude.
Defensible 2026 add-backs in an SEC filing: acquisition-related intangible amortization, time-bounded one-time integration costs, integration-tied restructuring charges, year-1 ASC 805 inventory step-up, and transaction expenses. SEC-challenged add-backs: “normalized” stock-based compensation, recurring restructuring presented as one-time, FX and tax true-ups labeled non-recurring, and adjustments not used by management internally.
Roughly 18 percent of U.S. private-target M&A deals in 2024 included an earnout per the ABA Private Target Deal Points Study. The accounting treatment under ASC 805 is unusual: contingent consideration is measured at fair value at close, recorded as a liability (cash earnout) or equity (fixed-share earnout), and re-measured at fair value through earnings each quarter until settled.
| Earnout structure | Close accounting | Subsequent treatment |
|---|---|---|
| Cash earnout on revenue/EBITDA hurdle | Fair value liability | Remeasured each quarter through P&L |
| Stock earnout, fixed share count if hurdle hit | Equity (no remeasurement) | No P&L impact, dilution captured at close |
| Stock earnout, variable share count | Fair value liability | Remeasured each quarter through P&L |
| Performance vesting for selling shareholders who stay as employees | Compensation expense over service period | Comp expense (not deal consideration), per ASC 805-10-55-25 |
The classification fight (deal consideration versus compensation expense) is a routine issue raised by auditors and the SEC staff. The five-factor test in ASC 805-10-55-25 turns on continued employment, level of compensation versus market, and whether the same arrangement is offered to all shareholders. Cooley and Wilson Sonsini both publish memos that walk through the test for tech founder earnouts (see Cooley Insight publications). For the broader corporate context see founder shares and what is a stock purchase agreement.
Breakeven Synergy Analysis and the EPS Bridge Chart
Once the base case bridge is built, the next analysis is the sensitivity. The most useful single output is the breakeven synergy number, the recurring pre-tax run-rate cost saving required to make the deal EPS-neutral in year 1.
Breakeven Run-Rate Synergy (pre-tax) = (Year 1 Dilution in dollars) / ((1 – Tax Rate) x Phasing Factor in Year 1)
For the worked example: year 1 dilution of $0.33 per share x 208.75M shares = $68.9M of after-tax dilution. Divide by (1 – 23%) = $89.5M pre-tax. Divide by year 1 cost synergy phasing of 25 percent = $358M of required run-rate synergy. The base case already includes $100M run-rate, so the gap to year 1 breakeven is $258M of additional run-rate synergy.
| Run-rate cost synergy | Year 1 accretion (dilution) | Year 2 | Year 3 |
|---|---|---|---|
| $50M run-rate | (5.8%) | (0.7%) | 2.3% |
| $100M run-rate (base case) | (5.5%) | 0.0% | 3.6% |
| $150M run-rate | (5.2%) | 0.7% | 4.9% |
| $200M run-rate | (4.9%) | 1.4% | 6.2% |
| $300M run-rate | (4.3%) | 2.8% | 8.8% |
| $358M run-rate (year 1 breakeven) | 0.0% | 3.6% | 10.3% |
The EPS bridge waterfall walks from standalone acquirer EPS to pro forma EPS, broken into 6 to 9 buckets. For the worked example year 1:
| EPS bridge bucket | Year 1 EPS impact | Cumulative EPS |
|---|---|---|
| Standalone acquirer EPS | n/a | $6.00 |
| + Target net income contribution | +$0.44 | $6.44 |
| – Share count dilution | -$0.27 | $6.17 |
| + Cost synergies (after-tax, phased) | +$0.09 | $6.26 |
| – Integration costs (after-tax) | -$0.15 | $6.11 |
| – Intangible amortization (after-tax) | -$0.15 | $5.96 |
| – Incremental net interest (after-tax) | -$0.45 | $5.51 |
| + Tax shield rounding and timing | +$0.16 | $5.67 |
| Pro forma EPS | n/a | $5.67 |
The chart immediately telegraphs the story: net interest expense is the single largest dilutive driver in year 1, and cost synergies barely cover integration costs through year 1. The board will press for either lower premium, more cash, or a faster synergy ramp.
Tax Structuring: 338(h)(10), 336(e), and Section 197
For taxable asset acquisitions or transactions treated as asset acquisitions via an election under IRC Section 338(h)(10) or Section 336(e), the acquirer gets a step-up in the tax basis of the acquired assets. The step-up creates additional tax-deductible amortization under IRC Section 197, which permits 15-year straight-line amortization of acquired intangibles for tax purposes. The 197 amortization is a major tax shield and feeds the accretion dilution model via a lower effective tax rate on pro forma earnings. The trade-off: selling shareholders are typically asked to pay more tax up front, so they demand a gross-up in purchase price. Modeling the gross-up correctly versus the present value of the tax shield is the difference between a profitable structure and a wash. For a deeper treatment see installment sale vs cash sale business.
| Structure | Tax treatment | Step-up? | Accretion impact |
|---|---|---|---|
| Stock purchase, no election | Tax-deferred to buyer; buyer inherits attributes (382-limited) | No | No 197 amortization, lower tax shield |
| Stock purchase + 338(h)(10) (S-corp or QSub target) | Treated as asset sale for tax | Yes | 15-year 197 amortization, often 1 to 4 percent extra accretion |
| Stock purchase + 338(g) (foreign target) | Asset sale for tax, used for CFC structures | Yes | Buyer-friendly, often used with subpart F planning |
| Section 336(e) (corporate seller of subsidiary) | Asset sale for tax | Yes | Similar to 338(h)(10) |
| Asset purchase | Asset sale for both tax and book | Yes | Full step-up, double tax in C-corp seller case |
| Reverse triangular merger qualifying as 368(a)(1)(A) | Tax-free to seller if stock consideration meets continuity rules | No | No tax shield but enables tax-free rollover |
For the QSBS angle on founder-favored structures see QSBS Section 1202 small business stock. For change-of-control equity-side payout protections, see golden parachute 280G and material adverse effect.
Three Real-World Case Studies
Patterns repeat. Three deals from the 2023-2024 cycle that bankers reference when training new associates:
ExxonMobil acquires Pioneer Natural Resources (October 2023). $59.5 billion all-stock deal at 2.3234 ExxonMobil shares per Pioneer share. ExxonMobil disclosed expectation of “double-digit cash flow per share accretion” within five years driven by $1B annual cost synergies and Permian Basin operational integration. Reuters and the Wall Street Journal both published EPS bridge breakdowns within 48 hours; first-year accretion modeled at roughly 4 to 6 percent on consensus 2024 numbers (see Reuters Deals coverage).
Chevron acquires Hess Corporation (October 2023). $53 billion all-stock deal at 1.025 Chevron shares per Hess share. Chevron emphasized free cash flow per share accretion over GAAP EPS. The Stabroek block stake in Guyana was the strategic prize. Bloomberg and the FT modeled year-2 accretion (post-arbitration on ExxonMobil’s right of first refusal) at 3 to 5 percent on cash flow per share, lower on GAAP EPS because of intangible amortization on the Stabroek interest (see FT oil and gas coverage).
Cisco acquires Splunk (March 2024 close, $28 billion all-cash). Funded with $25 billion of new debt across 5, 7, 10, and 30-year tranches priced February 2024. Cisco disclosed expectation of being non-GAAP EPS accretive in year 1 and GAAP EPS accretive in year 3, with $1.0 billion of expected annual cost synergies by year 3. The cash-only structure plus the BBB+ credit cushioned the EPS hit but added meaningful debt. S&P and Moody’s both wrote up the credit angle (see S&P Global Ratings research and Moody’s ratings research).
Each deal teaches a different lesson. ExxonMobil: large all-stock deals can be accretive at scale if peer trading multiples align and integration synergies are credible. Chevron: cash flow per share is sometimes the more honest metric than GAAP EPS for capital-intensive industries. Cisco: when an acquirer’s stock trades at a high multiple but cost of debt is low, the cash-funded structure may dilute GAAP EPS but preserve the equity story.
Where Accretion Dilution Fits in the Banker Workflow
An accretion dilution model is one of four valuation and structural outputs the deal team builds on every sell-side mandate or strategic bolt-on:
| Model | Answers the question | Audience |
|---|---|---|
| Discounted cash flow | Intrinsic value of the target | Acquirer board, fairness committee |
| Comparable company analysis | What public peers trade at today | Acquirer board, target board |
| Precedent transactions | What buyers have paid in recent deals | Target board, sell-side bankers |
| Accretion dilution | Will this deal raise or lower acquirer EPS | Acquirer board, equity analysts, ratings agencies, proxy advisors |
The fairness opinion delivered by the bank covers the first three. The accretion dilution is delivered as a separate strategic and financial analysis to the acquirer board, almost never as a standalone fairness exhibit because it speaks only to the acquirer’s accounting outcome and not to the value exchanged. See our deeper walkthroughs at discounted cash flow business valuation, DCF valuation for a business sale in 2026, business valuation formula methods and math, and how to determine the value of a business.
For private-equity bidders the analog is the LBO model, which solves for the bidder’s internal rate of return rather than a public-market EPS impact. See leveraged buyout model from scratch, LBO model step-by-step guide, and paper LBO example walkthrough for the parallel methodology. PE analyst career mechanics sit at private equity analyst career guide.
Common Mistakes and Sanity Checks Before the Board Meeting
The same errors recur in junior-banker work, board books, and even printed proxies. The most expensive ones:
- Using LTM target EPS instead of forward EPS. The deal contributes future earnings, not historical ones. Anchoring on LTM net income systematically under-states accretion for a growing target.
- Forgetting to gross up for transaction fees and capitalized financing costs. The fees are real and reduce day-one cash, which reduces foregone interest income (a non-obvious double effect).
- Mismatching share count basis. Standalone acquirer EPS is on a diluted basis (treasury method for options and RSUs). The pro forma share count must also be diluted with both acquirer and target dilutive securities included.
- Double-counting synergies and revenue. If the target’s standalone forecast already includes some pricing harmonization assumed by the acquirer, the synergy line double-counts. Strip the target forecast back to a “no-deal” base case before layering deal synergies.
- Ignoring step-up amortization on equity-method or noncontrolling interest holdings. JVs and NCIs inside the target carry their own purchase accounting and amortization streams.
- Failing to update for share count creep. Acquirer net income and share count must be projected forward on a like-for-like basis, including buybacks and dilutive grants. The deal does not freeze the standalone forecast.
- Misclassifying earnouts as deal consideration when they are compensation. See the ASC 805-10-55-25 five-factor test above.
- Forgetting the foregone interest income tax effect. Interest income on excess cash is taxed at the marginal rate. Losing the interest reduces both pre-tax income and the related tax expense.
Three sanity checks every analyst runs the morning of the committee meeting. First, the Rule of P/E sanity: compute acquirer P/E and implied target P/E paid. If acquirer P/E is higher, all-stock structure should be mechanically accretive before synergies. If the model shows the opposite, find the bug. Second, the after-tax cost of capital test: sum up the weighted after-tax cost of the financing mix and compare against target earnings yield (1 / target P/E paid). If after-tax cost of capital is below target earnings yield, the deal is accretive before synergies. Third, the breakeven synergy stress test: compare your breakeven to publicly disclosed synergy estimates from similar deals in the sector. If your breakeven exceeds the 75th percentile of recent comparable deals, the model is at risk. The Securities and Exchange Commission’s Financial Reporting Manual Section 3000 covers pro forma disclosure requirements that govern how each of these items must appear in registration statements and proxies.
Regulatory Footprint and Proxy Advisor Vote Math
An accretion dilution model is not in itself a regulated disclosure, but the numbers that derive from it are. In a public-target deal the merger proxy filed under SEC Schedule 14A requires pro forma financial statements under Regulation S-X Article 11, as amended in 2020. Article 11 requires a pro forma condensed balance sheet as of the most recent date, a pro forma condensed income statement for the most recent fiscal year and any interim period, and (optionally) management adjustments that include synergies, anticipated cost savings, and integration costs.
The 2020 amendment was significant because it permitted management adjustments to appear in the pro forma presentation for the first time. Prior to the amendment, only transaction accounting adjustments and autonomous entity adjustments were permitted. The full text sits in the SEC final release at SEC Release 33-10786 Amendments to Financial Disclosures about Acquired and Disposed Businesses. The Wachtell Lipton client memo from May 2020 (see Wachtell Publications) is the standard practitioner reference. Hart-Scott-Rodino merger reviews where the deal exceeds the size-of-transaction threshold ($126.4 million for 2026 per FTC annual revision under 16 CFR 801) sometimes pull the accretion dilution model into Item 4(c) and 4(d) document production.
For deals requiring an acquirer shareholder vote (typically NYSE Rule 312.03 or Nasdaq Rule 5635, both requiring shareholder approval for share issuances of 20 percent or more), the accretion dilution analysis becomes the central proxy advisor talking point. ISS and Glass Lewis both publish methodology notes on M&A vote evaluation (ISS proxy voting policies and Glass Lewis voting policies). Factors that move vote recommendations from FOR to AGAINST on the acquirer side: greater than 5 percent EPS dilution in year 1 with no clear path to accretion in year 3; significant debt increase (pro forma net debt to EBITDA exceeding 3.5x or 4.0x) without ratings agency assurance; acquirer stock issuance exceeding 50 percent of pre-deal market cap; lack of independent fairness opinion or financial advisor with material conflict; synergy projections unsupported by management track record on prior deals.
Standard modeling conventions have not changed in 20 years: blue for hard inputs, black for formulas, green for cross-tab links, red for outputs that flow to the deck; tabs ordered Inputs / Acquirer Stand-Alone / Target Stand-Alone / Synergies / Financing / Pro Forma IS / EPS Bridge / Sensitivity / Outputs; historical 2 years plus deal LTM plus 5 pro forma years. Capital IQ, FactSet, and Bloomberg do not produce automated A/D outputs because deal-specific assumptions vary too much. Templates published by Wall Street Prep, Macabacus, and the Corporate Finance Institute accretion dilution course and the Wall Street Prep accretion dilution primer are the two most-cited training references for first-year associates.
TLDR and Key Takeaways
- Accretion dilution analysis measures the change in pro forma diluted EPS in years 1, 2, and 3 versus standalone acquirer EPS. Positive equals accretive, negative equals dilutive.
- The formula is pro forma net income (acquirer plus target plus after-tax synergies minus after-tax incremental interest, intangible amortization, and integration costs) divided by pro forma diluted share count.
- Four drivers decide the answer: financing mix, premium paid, synergy run-rate and phasing, and the Rule of P/E (acquirer P/E versus implied target P/E in stock deals).
- Cost synergies materialize at roughly 80 percent of announcement; revenue synergies at roughly 50 percent, per the McKinsey M&A research base.
- Purchase price allocation under ASC 805 creates non-cash intangible amortization that often makes GAAP year 1 dilutive while adjusted (cash) EPS is accretive. Both numbers are presented to the board.
- Breakeven synergy is the recurring run-rate pre-tax cost saving required to make year 1 EPS-neutral. It is the single most useful sensitivity output.
- SEC Article 11 governs the pro forma financial statement disclosure that flows from the model into the merger proxy. The 2020 amendments permit management synergy adjustments with detailed footnote support.
- Proxy advisors (ISS, Glass Lewis) flag deals with more than 5 percent year 1 EPS dilution and no clear year 3 accretion path. Acquirer vote outcomes can swing on this single metric.
- The model is one of four standard outputs (DCF, trading comps, precedent transactions, accretion dilution) and is the only one that speaks to acquirer-specific accounting outcomes rather than to value exchanged.
- The most common modeling mistakes (LTM versus forward EPS, double-counted synergies, mismatched diluted share counts, ignored foregone interest tax effect, misclassified earnout as deal consideration) all bias the answer toward overstated accretion. Defensive review catches them before they hit the deck.